WO2000008054A1

WO2000008054A1 - Modified green fluorescent protein

Info

Publication number: WO2000008054A1
Application number: PCT/GB1999/002596
Authority: WO
Inventors: Philippe Bastiaens; Rainer Pepperkok; Stefan Geley
Original assignee: Imperial Cancer Research Technology Limited
Priority date: 1998-08-08
Filing date: 1999-08-06
Publication date: 2000-02-17
Also published as: WO2000008444A1; AU5429299A; EP1102976A1; AU5429399A; WO2000008443A1; JP2002542453A; AU5429199A; EP1102977A1; EP1102791A1; WO2000008443A9; JP2002522040A

Abstract

A polypeptide comprising the functional portion of green fluorescent protein but wherein valine (V) (163) has been replaced with alanine (A), serine (S) (175) has been replaced with glycine (G), isoleucine (I) (167) has been replaced with threonine (T), phenylalanine (F) (64) has been replaced with leucine (L), serine (S) (65) has been replaced with threonine (T), serine (S) (72) has been replaced with alanine (A), and threonine (T) (203) has been replaced with tyrosine (Y). Polynucleotides encoding the protein and uses of the protein as a reporter molecule are also described.

Description

MODIFIED GREEN FLUORESCENT PROTEIN

The present invention relates to fluorescent proteins, in particular to "green fluorescent proteins" (GFPs) and mutants thereof which have altered spectral properties compared to the wild type GFP.

Fluorescent assays for biological systems have been used for several years since, compared to many biological techniques, they have the advantage of, in some circumstances, being able to be carried out non-invasively and also they are able to give real time analysis of particular reactions in complex biological systems in which many reactions are being carried out simultaneously. In conjunction with the development of physical techniques for fluorescent assays has been the development of biological reporter constructs which serve as monitors of reactions, for example, within a cell. In particular, the development of fluorescent proteins that do not require cofactors for their intrinsic fluorescence has meant that such proteins can be introduced into and expressed in cells via genetic constructs.

Examples of intrinsically fluorescent proteins, notably so-called Aequorea victoria "green fluorescent proteins" or "GFPs" (although they may be blue or yellow) are known. Miyawaki et al (1997) Nature 388, 882-887 describes a GFP-based Ca²⁺ sensing system; Mitra et al (1996) Gene 173, 13-17 describes a rwo-GFP-based system for use in identifying protease inhibitors; WO 97/28261 discloses a two-GFP system in which the GFP donor and GFP acceptor are linked by a peptide containing a protease cleavage site. WO 95/07463 describes uses of GFPs; WO 96/23898 relates to a method of detecting biologically active substances using GFPs; Heim & Tsien (1996) Current Biology 6, 178-182 relates to engineered GFPs with improved brightness, longer wavelengths and fluorescence resonance energy transfer (FRET); Poppenborg et al (1997) J. Biotechnol. 58, 79-88 relates to GFPs as reporters for bioprocess monitoring; Park & Raines (1997) Protein Science 6, 2344-2349 relates to a GFP as a signal for protein-protein interactions; Niswender et al (1995) J. Microscopy 180, 109-116 relates to quantitative imaging of GFP in cultured cells; Chalfie et al (1994) Science 263, 802-805 relates to GFP as a marker for gene expression; Hampton et al (1996) Proc. Natl. Acad. Sci. USA 93, 828-833 relates to the in vivo examination of membrane protein localization and degradation with GFP; Heim et al (1995) Nature 373, 663-664 relates to mutant GFPs with altered fluorescent properties; Mosser et al (1997) BioTechniques 22, 150-161 relates to the use of a dicistronic expression cassette encoding GFP for the screening and selection of cells expressing inducible gene products; Suarez et al (1997) Gene 196, 69-74 relates to GFP-based reporter systems for genetic analysis of bacteria; Niedenthal et al (1996) Yeast 12, 773-778 relates to GFP as a marker for gene expression and subcellular localization in budding yeast; and Prescott et al (1997) FEBS Lett 411, 97-101 relates to the use of GFP as a marker for assembled mitochondrial ATP synthase in yeast. GFPs and their uses have been reviewed in Pozzan et al (1997) Nature 388, 834-835, Misteli & Spector (1997) Nature Biotechnology 15, 961-964; and Cubitt et al (1995) Trends Biochem. Sci. 20, 448-455.

Despite many variant GFPs being known, there continues to be the need for variant GFPs which have improved properties, especially improved or new spectral properties, for use in biological systems, especially those where fluorescence resonance energy transfer (FRET) is used to study the biological system.

An example of a FRET-based method for studying biological systems is described in detail in UK Patent Application No 9817229.9 entitled "Fluorescent assay for biological systems" and the PCT application claiming priority from that application and which was filed on the same day as this application. A further example of a FRET-based method is described in Miyawaki et al (1997) Nature 388, 882-887.

A first aspect of the invention provides a polypeptide comprising the functional portion of green fluorescent protein but wherein valine (V) 163 has been replaced with alanine (A), serine (S) 175 has been replaced with glycine (G), isoleucine (I) 167 has been replaced with threonine (T), phenylalanine (F) 64 has been replaced with leucine (L), serine (S) 65 has been replaced with threonine (T), serine (S) 72 has been replaced with alanine (A), and threonine (T) 203 has been replaced with tyrosine (Y).

By "functional portion" we include the meaning that it is the portion of the protein which, in the absence of other portions of GFP, gives rise to useful fluorescent properties, such as the portion being fluorescent. It will be appreciated that, in respect of this first aspect of the invention the GFP or polypeptide comprising the functional portion of GFP with the given mutations may also include other mutations which may confer further desirable properties. A second aspect of the invention provides a polypeptide which has the amino acid sequence

MGKGEELFTGWP I LVELDGDVNGQKFS VRGEGEGDATYGKLTLKF I CTTGKLPVP PTLVTTLTY GVQCFARYPDHMKR HDFLKSAMPEGYVQERTIFFKDDGNYϊO'I ^VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYN' SHNVYII^LADKQKNG

IK^NF- ^RHNIEDGGVQI_ADHYQQm^,PIGDGPV LPD_røY SYQSA SQDPHG-α^_I^-VLLEFVTS AGITHG DELYKSF

This is the sequence shown in Figure 3.

Conveniently, the difference with respect to the native GFP can be summarised as S2G, H25Q, S30R, F64L, S65T, S72A, Q80R, F84L, V163A, I167T, S175G, T203Y, K209Q, N212H, E213G, A216S, + 239S + 240F, making use of standard single letter amino acid code.

By "green fluorescent protein", in the context of a single protein, we mean wild-type green fluorescent protein as described in Prasher et al (1992) Gene 111, 229-233 and whose amino acid sequence is given in Figure 1. As noted above, the term GFP may be used to denote variants which in fact fluoresce yellow or blue.

The sequence of a particular preferred polypeptide of the invention (variant GFP) is shown in Figure 3, and its sequence is compared with A. victoria GFP and mm GFP5 (Zernicka-Goeta et al (1997) Development \2A, 1133-1137 in Figures 4 and 5.

It will be appreciated that the functional portion of the polypeptide which contains the mutations as said may be incorporated into any suitable polypeptide in which it is desired to have a fluorescent moiety. Typically, the functional portion is included in a polypeptide whose fluorescence or change in fluorescence is measured under suitable conditions. Thus, the polypeptide may be one which is expressed as a reporter molecule (since its expression may be measured fluorimetrically). Alternatively, the functional portion may be included in a polypeptide which is used in a biological system which makes use of FRET. For example, a polypeptide of the invention includes a polypeptide which contains the fluorescent portion as said, and it is used in conjunction with another fluorescent moiety with which it acts as a donor or acceptor in a FRET reaction. Most suitably, the polypeptide of the invention contains, in addition to the functional portion as said, a further fluorescent moiety in the same polypeptide chain and the pair of fluorescent moieties may act as donor- acceptor pairs in a FRET reaction. Thus, the polypeptide of the invention typically is a fusion protein containing at least the functional portion of the polypeptide which contains the mutations as said.

Thus, the polypeptide of the invention may be used in any suitable prior art FRET method.

The polypeptides of the invention are particularly suited for use in the FRET method described in UK Patent Application No 9817229.9 entitled "Fluorescent assay for biological systems" and the PCT application claiming priority from that application and which was filed on the same day as this application since the mutations confer an unusually high fluorescent lifetime. The polypeptides of the invention are believed to be particularly suited as acceptor molecules since, at least in relation to the molecule of the second aspect of the invention, it excites at 514nm and emits at 531nm.

A particularly preferred polypeptide of the invention is one which has the amino acid sequence as shown in Figure 3.

A further preferred polypeptide of the invention is one which comprises at least residues 7 to 229 of green fluorescent protein containing said amino acid replacements. The minimal domain required for fluorescence in GFP is believed to be amino acids 7 to 229 (Li et al (1997) J. Biol. Chem. 272, 28545-28549. Also, this information, and other information about GFPs, is available from Clontech Laboratories, Inc., 1020 East Meadow Circle, Palo Alto, CA 94303, USA (xqli@CLONTECH . com) .

It is preferred that a polypeptide which comprises at least residues 7 to 229 of green fluorescent protein not only contains the amino acid replacements described with respect to the first aspect of the invention, but also, compared to native A. victoria GFP, the amino acid replacements H25Q, S30R, Q80R, F84L, K209Q, N212H, F213G and A216S.

A still further preferred polypeptide is one comprising a further fluorescent moiety. In particular, the further fluorescent moiety is one which is capable of FRET with the said portion of the variant GFP. Typically, this further fluorescent moiety is a GFP or a variant GFP. Thus, a particularly preferred polypeptide of the invention is a fusion polypeptide which contains at least the functional portion of the polypeptide which contains the mutations as said, and contains a further mutant GFP.

A third aspect of the invention provides a polynucleotide encoding a polypeptide of the first or second aspect of the invention. The polynucleotide may be DNA or RNA; DNA is preferred. A particularly preferred polynucleotide of the invention is shown in Figure 3 (DNA sequence) but, because of the degeneracy of the genetic code, it will be appreciated that other polynucleotides may encode the same polypeptide (ie with the amino acid sequence given in Figure 3).

A fourth aspect of the invention provides an expression vector encoding a polypeptide of the first or second aspect of the invention.

The expression vectors of the invention, and other polynucleotides can be constructed by standard laboratory molecular biology methods such as those described in Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York incorporated herein by reference.

The polynucleotide of the invention (typically DNA) may be expressed in a suitable host to produce a polypeptide comprising the polypeptide of the invention. Thus, the DNA encoding the polypeptide of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter et al, 4,530,901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crowl, 4,677,063 issued 30 June 1987 to Mark et al, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura et al, 4,710,463 issued 1 December 1987 to Murray, 4,757,006 issued 12 July 1988 to Toole, Jr. et al, 4,766,075 issued 23 August 1988 to Goeddel et al and 4,810,648 issued 7 March 1989 to Stalker, all of which are incorporated herein by reference.

The polynucleotide, such as DNA, encoding the polypeptide of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

Many expression systems are known, including bacteria (for example E. coli and Bacillus subtilis), yeasts (for example Saccharomyces cerevisiae), filamentous fungi (for example Aspergillus), plant cells, animal cells and insect cells.

The vectors include a prokaryotic replicon, such as the CoIEl ori, for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as E. coli, transformed therewith.

A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention. Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and p7rc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.

A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells.

An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long teπninal repeat to drive expression of the cloned gene.

Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (Yips) and incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (YCps).

A variety of methods have been developed to operably link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted into the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules. Synthetic linkers containing one _or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion, is treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding, 3' -single-stranded termini with their 3'-5'- exonucleolytic activities, and fill in recessed 3 '-ends with their polymerizing activities.

The combination of these activities therefore generates blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.

A desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki et al (1988) Science 239, 487-491. In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic. Bacterial cells are preferred prokaryotic host cells and typically are a strain of E. coli such as, for example, the E. coli strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic cell line. Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, and monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650.

Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al (1972) Proc. Natl. Acad. Sci. USA 69, 2110 and Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman et al (1986) Methods In Yeast Genetics, A Laboratory Manual, Cold Spring Harbor, NY. The method of Beggs (1978) Nature 275, 104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA.

Electroporation is also useful for transforming cells and is well known in the art for traiiisfonning yeast cells, bacterial cells and vertebrate cells.

For example, many bacterial species may be transformed by the methods described in Luchansky et al (1988) Mol. Microbiol. 2, 637-646 incorporated herein by reference. The greatest number of transformants is consistently recovered following electroporation of the DNA-cell mixture suspended in 2.5X PEB using 6250V per cm at 25μFD.

Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) Methods Enzymol. 194, 182.

Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the invention. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) J. Mol. Biol. 98, 503 or Berent et al (1985) Biotech. 3, 208. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

However, a convenient way of identifying transformed cells which express the polypeptide is that they are fluorescent.

In addition to directly assaying for the presence of recombinant DNA, successful transformation can be confirmed by well known immunological methods when the recombinant DNA is capable of directing the expression of the protein. For example, cells successfully transformed with an expression vector produce proteins displaying appropriate antigenicity.

Samples of cells suspected of being transformed are harvested and assayed for the protein using suitable antibodies. Of course, transformation and expression is indicated by the production of a fluorescent protein in this case.

Thus, in addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium.

A particularly suitable "starting" vector is the pcDNA3.1 vector distributed by Invitrogen (Invitrogen BN, De Schelp 12, 9351 ΝN Leek,

The Netherlands). The key features of this vector for this invention are: (i)

Cytomegalovirus enhancer-promoter for high level expression of the insert in mammalian cells (the insert is for example the cDNA encoding the polypeptides described above and- has to be cloned into the vector); (ii) multiple cloning site in forward and reverse orientation; (iii) expression cassette for a selectable marker in eukaryotic cells (neomycin, zeocin or hygromycin).

When the polypeptide of the invention is to be used ex vivo, such as in an in vitro assay or the like, it may be convenient to express the polypeptide in a bacterial system (such as E. coli), or in yeast or insect cells, or in other systems which have been designed for facile production of large amounts of protein. When the polypeptide of the invention is to be used in an in vivo assay it is conveniently expressed in the cell in which the assay is to be carried out, typically a mammalian cell.

In a particularly preferred embodiment, DNA encoding the polypeptide of the invention (such as YFP5) may be fused to the promoter/enhancer elements of a gene under investigation. Such DNA stably introduced into mammalian cells may be used as a reporter for expression of the respective gene under investigation. Readout of the activity is the amount of polypeptide, such as YFP5, expressed, which can be determined by determination of the specific fluorescence of the polypeptide. Similar DNAs may be generated for the other GFPs such as those listed in Table 1 (see below). Since they have overlapping spectra they cannot be used simultaneously in the same cells. However, using fluorescent lifetime imaging CFP, MmGFP5 and YFP5, for example, could be used simultaneously as their lifetimes are sufficiently separated from each other. Using multiple frequency FLIM (fluorescent lifetime imaging) the relative amounts of these three GFP mutants expressed in the same cell could be determined with high precision and hence the promoter activity of at least three genes.

Multifrequency FLIM is described in UK Patent Application No 9817227.3 entitled "Multiple Frequency Fluorescence Lifetime Imaging" and the PCT application claiming priority from that application and which has the same filing date as this application.

The invention will now be described in more detail with reference to the following Figures and Example wherein:

Figure 1 shows the cDNA and amino acid sequence of A. victoria green fluorescent protein (GFP).

Figure 2 shows the cDNA and amino acid sequence of a prior art mutant GFP (mmGFP5; Zernicka-Goetz et at).

Figure 3 shows the cDNA and amino acid sequence of a polypeptide of the invention (called mmYFP or mYFP5 or YFP5) which is described in more detail in Example 1.

Figure 4 is a comparison of the cDNA sequences from Figures 1 to 3.

Figure 5 is a comparison of the amino acid sequences from Figures 1 to 3. Example 1: Construction of mutant GFP and its properties

The mutant GFP which we call YFP5, which is a red-shifted mutant of MmGFP5, was generated by PCR-mediated site-directed mutagenesis of MmGFP5 (Zernicka-Goetz et al (1997) Development 124, 1133-1137). MmGFP5 is a wtGFP mutated in V163A, S175G, I167T, F64L and S65T; the mutations N163A, S175G and I167T were introduced into wtGFP by Siemering et al (1996) Current Biol. 6, 1653-, and Zernicka- Goetz et al introduced the mutations F64L and S65T). This approach introduced mutations S72A and T203Y into MmGFP5 using primer pairs

ATGCGGCCGCGAATTCGCCACCATGGGTAAAGGAGAAGAACTT and

CTGGGTATCTTGCGAAGCATTGTACGTACAATGCTTCGCAAGATACCCAG; and

GAAAGGGCAGATTGATAGGACAGGTAATGCATTACCTGTCCTATAATCTGCCCTT

TC and AAGGATCCTCTAGAAGCTTTTGTATAGTTCATCCATG. The underlined nucleotides indicate mismatches.

The fluorescent lifetimes of various GFP mutants are shown in Table 1.

References to Table 1

1. Heim & Tsien (1996). Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer. Curr. Bio. 6, 178-182.

2. Orme M et al (1996). Crystal structure of the Aequorea victoria green fluorescent protein. Science 273, 1392-1395. 3. Zernicka-Goetz et al (1997). Following cell fate in the living mouse embryo. Development 124, 1133-1137.

4. Miyawaki et al (1997). Fluorescent indicators for Ca²⁺ based on green fluorescent proteins and calmodulin. Nature 388, 882-887.

The final PCR product was gel-purified, digested with ϋcoRI and Xbάl and subcloned into pEFT7MCS. This vector is based on pEF-BOS (Nucleic Acids Res. (1990) Sep 11; 18(17), 5322 pEF-BOS, a powerful mammalian expression vector. Mizushima S, Nagata S). A modified version of pEF-BOS containing a Neo resistance expression cassette, pEFl-Neo, was obtained from G. Baier, Innsbruck. The Neo expression cassette to make the vector smaller and introduced a T7 RNA polymerase promoter as well as several unique restriction enzyme sites downstream of the human EFlα promoter and the SV40 polyadenylation site.

Any other suitable vector, as described in the specification, may be used for the expression of the mutant GFP. The introduced mutations were verified by sequencing using Sequenase. The sequence of YFP5 is given in Figure 3.

The respective GFP mutants were expressed in cells by microinjection (Pepperkok et al, 1997 in "Microinjection and Transgenesis", eds. Cid- Arregui and Garcia-Carranca, Springer, Heidelberg, pp 145-154) of plasmids based on the vector pEFT7MCS and with inserts of the respective GFP encoding cDNAs. At 2h after microinjection cells were mounted on the FLIM microscope set-up and the respective lifetimes were determined at 37 °C in living cells. Any suitable expression system or lifetime-detection system may be used.

YFP5 shows a well-separated and significantly longer lifetime than other GFP mutants making it an ideal partner in multi-labelling FLIM experiments.

Table 1: Fluorescent lifetimes of various GFP mutants.

* : numbers in parenthesis are the side-peaks in excitation and emission of CFP which are used in the single excitation wavelength method to measure FRET by "ingrowth". The fluorescent life-time was measured by excitation at 488nm.

Claims

1. A polypeptide comprising the functional portion of green fluorescent protein but wherein valine (V) 163 has been replaced with alanine (A), serine (S) 175 has been replaced with glycine (G), isoleucine (I) 167 has been replaced with threonine (T), phenylalanine (F) 64 has been replaced with leucine (L), serine (S) 65 has been replaced with threonine (T), serine (S) 72 has been replaced with alanine (A), and threonine (T) 203 has been replaced with tyrosine (Y).

2. A polypeptide which has the amino acid sequence

MGKGEE FTGWPILVELDGDVNGQIFSVRGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTT TY GVQCFARYPDHMKR HDFLKSAMPEGYVQERTIFFKDDG YKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYN SHNVYIMADKQKNG

IKA FKT_ IEDGGVQLADHYQQNTPIGDGPVLLPD_raYLSYQSALSQDPHGK_^HMV LEFVTS AGITHGMDELYKSF .

3. A polypeptide according to Claim 1 which has the additional amino acid replacements S2G, H25Q, S30R, Q80R, F84L, N212H, E213G, A216S, and additional residues 239S and 240F.

4. A polypeptide comprising at least residues 7 to 229 of green fluorescent protein containing the amino acid replacements as defined in any of Claims 1 to 3.

5. A polypeptide according to any one of Claims 1, 3 and 4 comprising a further fluorescent moiety.

6. A polypeptide according to Claim 5 wherein the further fluorescent moiety is a green fluorescent protein or a variant thereof.

7. A polypeptide according to any one of Claims 1, and 3 to 6 which is a fusion polypeptide.

8. A polypeptide according to Claim 7 wherein the fusion polypeptide is one used in a biological system which makes use of FRET.

9. A polynucleotide encoding a polypeptide according to any one of the preceding claims.

10. An expression vector encoding a polypeptide according to any one of Claims 1 to 8.

11. A host cell comprising a polynucleotide according to Claim 9 or an expression vector according to Claim 10.

12. Use of a polypeptide according to any one of Claims 1 to 8 as a reporter molecule in a cell.

13. Use of a polynucleotide according to Claim 9 or an expression vector according to Claim 8 to express a reporter molecule in a cell.

4. Any novel fluorescent protein as herein described.